|  |
| --- |
| Supplementary Table S4. Clinical factors of higher and inappropriately lower measured HbA1c compared with target HbA1c by multivariate logistic regression analysis in patients with drugs potentially associated with severe hypoglycemia classified as Categories I and II |
|  |  |  |  |
| Clinical factors of higher measured HbA1c than target HbA1c |
| 　 | Odds ratio | 95% CI | *P* value |
| Category II / Category I | 1.0617 | 0.4953 to 2.2643 | 0.8767 |
| BMI (kg/m2) | 1.1022 | 1.0128 to 1.2066 | 0.0282\* |
| FPG (mg/dL) | 1.0118 | 1.0042 to 1.0205 | 0.0041\* |
| Use of GLP‐1 receptor agonist | 2.2401 | 0.7745 to 6.7262 | 0.1374 |
| Use of DPP-4 inhibitor | 1.1137 | 0.4544 to 2.7833 | 0.8143 |
| Use of SGLT2 inhibitor | 1.3266 | 0.6268 to 2.8362 | 0.4603 |
|  |  |  |  |
| Clinical factors of inappropriately lower measured HbA1c than target HbA1c |  |
| 　 | Odds ratio | 95% CI | *P* value |
| Category II / Category I | 1.8993 | 0.7757 to 4.7091 | 0.1597 |
| BMI (kg/m2) | 1.0921 | 0.9805 to 1.2236 | 0.1141 |
| FPG (mg/dL) | 0.9954 | 0.9833 to 1.0068 | 0.4416 |
| Use of GLP‐1 receptor agonist | 0.4829 | 0.0921 to 2.2449 | 0.3573 |
| Use of DPP-4 inhibitor | 1.1512 | 0.3944 to 3.5550 | 0.7988 |
| Use of SGLT2 inhibitor | 0.2055 | 0.0492 to 0.6640 | 0.0067\* |

BMI: body mass index; FPG: fasting plasma glucose;

GLP‐1: glucagon‐like peptide‐1; DPP‐4: dipeptidyl peptidase‐4; SGLT2: sodium-glucose cotransporter 2